BioPharmSignal logoBioPharmSignal

Biotech News

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

UnitedHealth Group (UNH)UnitedHealth GroupCompany update

UNH (UNH) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is unh.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

UNHUnitedHealth Group2026-05-26 11:00 EST

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

UNHUnitedHealth Group2026-05-21 12:00 EST

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

MDPediatrix Medical Group, Inc.2026-02-09 11:45 EST

Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026

View all latest news

UnitedHealth Group

UnitedHealth Group is a diversified healthcare company with insurance, care delivery, and services operations through UnitedHealthcare and Optum. The company’s story is driven more by managed-care scale, services growth, and operating execution than by classic biotech catalysts.

Recent company news

UNHUnitedHealth Group2026-08-06 12:00 EST

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

UNHUnitedHealth Group2026-08-04 12:30 EST

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

UNHUnitedHealth Group2026-07-28 12:00 EST

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

UNHUnitedHealth Group2026-07-06 12:00 EST

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

UNHUnitedHealth Group2026-05-26 11:00 EST

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Stock data

Close
403.97 USD
Market cap
343.21B USD
Exchange
NYSE
Sector
Healthcare Services
Location
United States